Evaluation of PAS-diastase and carcinoembryonic antigen staining in the differential diagnosis of malignant mesothelioma and papillary serous carcinoma of the ovary

1986 ◽  
Vol 149 (2) ◽  
pp. 133-141 ◽  
Author(s):  
Paul B. Silcocks ◽  
Amanda Herbert ◽  
Dennis H. Wright
Keyword(s):  
Differential Diagnosis ◽  
Carcinoembryonic Antigen ◽  
Malignant Mesothelioma ◽  
Serous Carcinoma ◽  
Papillary Serous Carcinoma ◽  
Carcinoma Of The Ovary

Papillary Serous Carcinoma of the Ovary: An Ultrastructural and Immunohistochemical Study

2004 ◽  
Vol 28 (3) ◽  
pp. 141-147 ◽  
Author(s):  
Zhenhe Suo ◽  
Kleonora Karbove ◽  
Claes Trope ◽  
Krassimir Metodiev ◽  
Jahn Nesland
Keyword(s):  
Immunohistochemical Study ◽  
Serous Carcinoma ◽  
Papillary Serous Carcinoma ◽  
Carcinoma Of The Ovary

scholarly journals Trisomy 8 in papillary serous carcinoma of the ovary studied by FISH

1999 ◽  
Vol 1 (2) ◽  
pp. 66-66
Author(s):  
A Afify ◽  
M Samy ◽  
C-L Sun ◽  
H F L Mark
Keyword(s):  
Serous Carcinoma ◽  
Trisomy 8 ◽  
Papillary Serous Carcinoma ◽  
Carcinoma Of The Ovary

Abstract 1714: Chemoresistance in patients with papillary serous carcinoma of the ovary

2011 ◽  
Author(s):  
Elizabeth H. Kerr ◽  
Peter J. Frederick ◽  
Denise K. Oelschlager ◽  
Hope Amm ◽  
Jeffery Sellers ◽  
...  
Keyword(s):  
Serous Carcinoma ◽  
Papillary Serous Carcinoma ◽  
Carcinoma Of The Ovary

Immunohistochemical characterization of endocervical papillary serous carcinoma

2006 ◽  
Vol 16 (Suppl 1) ◽  
pp. 286-292 ◽  
Author(s):  
S. Nofech-Mozes ◽  
G. Rasty ◽  
N. Ismiil ◽  
A. Covens ◽  
M. A. Khalifa
Keyword(s):  
Carcinoembryonic Antigen ◽  
Uterine Cervix ◽  
Serous Carcinoma ◽  
Control Group ◽  
Fallopian Tubes ◽  
Endocervical Adenocarcinoma ◽  
Conventional Cell ◽  
Papillary Serous Carcinoma ◽  
Histologic Subtypes

Endocervical adenocarcinomas are rare and aggressive neoplasms. Papillary serous endocervical adenocarcinomas are the rarest form of endocervical adenocarcinomas. This tumor exhibits morphologic similarities to its counterparts commonly seen in the endometrium, fallopian tubes, ovaries, and peritoneum, which are known to have an aggressive behavior. Because of the rarity of this tumor, little is known about its immunophenotyping. In this study, we included ten cases of papillary serous carcinomas arising from the uterine cervix (PSCC) diagnosed in the absence of a primary endometrial malignancy. We studied their immunohistochemical profile, using a panel of antibodies against Ki67, bcl-2, p53, carcinoembryonic antigen (CEA), and CD10, and compared them to 20 consecutive cases of cervical adenocarcinoma of conventional cell subtypes (CAC) (15 mucinous, 3 adenosquamous, and 2 endometrioid). Immunostaining was recorded semiquantitatively. Patients with PSCC ranged in age from 27 to 79 years (mean = 51.6 ± 19.1), while the conventional cell subtypes control group were 28–90 years old (mean = 47.5 ± 16.9). Only p53 and CEA immunostaining significantly correlated with the PSCC morphology (P= 0.001 and P= 0.016, respectively) as shown by Cochran–Mantel–Haenszel Statistics (Modified Ridit Scores). PSCC is a distinctive immunophenotypic subtype of endocervical adenocarcinoma with significantly higher p53 and lower CEA reactivity than other more common histologic subtypes.

Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary

2008 ◽  
Vol 18 (2) ◽  
pp. 379-383 ◽  
Author(s):  
A. Jaishuen ◽  
J. P. Berrios-Rivera ◽  
N. Sirisabya ◽  
H. G. Zheng ◽  
Y. Li ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Wound Healing ◽  
Recurrent Ovarian Cancer ◽  
Serous Carcinoma ◽  
Delayed Wound Healing ◽  
Erosive Osteoarthritis ◽  
First Case ◽  
Papillary Serous Carcinoma ◽  
Carcinoma Of The Ovary ◽  
Symptoms And Signs

Bevacizumab (BVC) is currently used in recurrent ovarian cancer and as part of the initial treatment for ovarian cancer. The most serious toxicities associated with BVC include gastrointestinal perforations, delayed wound healing, and hemorrhage. Arthritis had never been addressed in patients who received BVC treatment. This is the first case report of arthritis emergence linked to BVC administration. A 59-year-old female with recurrent ovarian cancer received multiple hormonal and cytotoxic regimens for 5 years and then developed erosive osteoarthritis of the hands secondary to BVC and paclitaxel. This effect was confirmed by a significant improvement in her symptoms and signs, after treatment was discontinued.

scholarly journals High-grade versus low-grade serous carcinoma of the ovary – current differential diagnosis and perspectives

2018 ◽  
Vol 53 (4) ◽  
pp. 557-562
Author(s):  
Manuela POPA ◽  
◽  
Adelina BIRCEANU COROBEA ◽  
Octavian MUNTEANU ◽  
Monica M. CIRSTOIU ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Serous Carcinoma ◽  
Low Grade ◽  
High Grade ◽  
Grade Versus ◽  
Carcinoma Of The Ovary
Sign in / Sign up

Export Citation Format

Share Document